| abstract |
The invention provides a class of DAT--5HT2 antagonists, packaged pharmaceuticals comprising such antagonists, and their uses in treating, or the manufacturing medicaments for treating disease conditions, inlcuding a movement disorder, attention deficit disorder or attention-deficit hyperactivity disorder, anxiety, depression or psychotic disorder. Related business methods such as marketing the inhibitors to healthcare providers are also provided. |